Cited 13 times in
Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박세호 | - |
dc.date.accessioned | 2018-03-26T16:41:40Z | - |
dc.date.available | 2018-03-26T16:41:40Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1738-6756 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/156721 | - |
dc.description.abstract | PURPOSE: This study aimed to evaluate the survival benefit of different adjuvant chemotherapy regimens in patients with T1-2N0 triple-negative breast cancer. METHODS: Of 67,321 patients who were registered in the Korean Breast Cancer Society nationwide database between January 1999 and December 2008, 4,033 patients with T1-2N0 triple-negative breast cancer were included. The overall survival of patients who did not receive adjuvant chemotherapy was compared with those treated with adjuvant anthracycline and cyclophosphamide (AC), 5-fluorouracil, anthracycline, and cyclophosphamide (FAC), or cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). RESULTS: The median follow-up was 52.5 months. Chemotherapy was used in 87.4% of patients; it was used more commonly in patients with T2 tumors, those who were younger, had a higher histologic grade, and who showed lymphovascular invasion. The 5-year cumulative overall survival rate was 95.4%. Younger age, breast-conserving surgery, and adjuvant chemotherapy were significantly associated with improved overall survival. The 5-year cumulative overall survival rate of patients who did not receive adjuvant chemotherapy and those treated with AC, FAC, and CMF were 92.5%, 95.9%, 95.3%, and 95.9%, respectively. On multivariate analysis, the administration of any adjuvant chemotherapy regimen was significantly associated with improved overall survival (p=0.038). No significant difference in survival benefit was observed among the three different treatment groups. CONCLUSION: A standard adjuvant chemotherapy regimen with the least drug-related toxicity might be a reasonable treatment for patients with T1-2N0 triple-negative breast cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean, English | - |
dc.publisher | Korean Breast Cancer Society | - |
dc.relation.isPartOf | JOURNAL OF BREAST CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Surgery | - |
dc.contributor.googleauthor | Hyun-Ah Kim | - |
dc.contributor.googleauthor | Min-Ki Seong | - |
dc.contributor.googleauthor | Eun-kyu Kim | - |
dc.contributor.googleauthor | Eunyoung Kang | - |
dc.contributor.googleauthor | Seho Park | - |
dc.contributor.googleauthor | Min Hee Hur | - |
dc.contributor.googleauthor | Byung Joo Song | - |
dc.contributor.googleauthor | Woo Chul Noh | - |
dc.identifier.doi | 10.4048/jbc.2015.18.3.271 | - |
dc.contributor.localId | A01524 | - |
dc.relation.journalcode | J01279 | - |
dc.identifier.eissn | 2092-9900 | - |
dc.identifier.pmid | 26472978 | - |
dc.subject.keyword | Adjuvant chemotherapy | - |
dc.subject.keyword | Lymph nodes | - |
dc.subject.keyword | Survival | - |
dc.subject.keyword | Triple negative breast neopla는 | - |
dc.contributor.alternativeName | Park, Se Ho | - |
dc.contributor.affiliatedAuthor | Park, Se Ho | - |
dc.citation.volume | 18 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 271 | - |
dc.citation.endPage | 278 | - |
dc.identifier.bibliographicCitation | JOURNAL OF BREAST CANCER, Vol.18(3) : 271-278, 2015 | - |
dc.identifier.rimsid | 39851 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.